HR Execs on the Move

Central Semiconductor

www.centralsemi.com

 
Central Semiconductor Corp. is a Hauppauge, NY-based company in the Computers and Electronics sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

micro lambda wireless inc

micro lambda wireless inc is a Fremont, CA-based company in the Computers & Electronics sector.

Texas Home Place

Texas Home Place is a Castroville, TX-based company in the Computers & Electronics sector.

Polar Semiconductor

Located in Bloomington, Minnesota, Polar Semiconductor is a wholly owned subsidiary of Sanken Electric Company, Ltd. We operate a 200,000 square-foot facility that includes 62,000 square feet of cleanroom space for wafer fabrication. Our manufacturing

Peraso Technologies

Peraso is a fabless semiconductor company specializing in the development of integrated circuits for the 60 GHz wireless marketplace. Peraso`s goal is to provide best in class products for the consumer electronics (CE) market in general, and specifically to the mobile segment, including smartphones, tablets, and digital cameras. As such, Peraso endeavors to incorporate features critical to the mobile market in our products, including minimal footprint, low power consumption and competitive price points. Peraso offers exciting new challenges in a dynamic entrepreneurial environment.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.